BYNFEZIA Pen

Product NDC: 62756-452
11-digit product format: 627560452
Labeler code: 62756
Product ID: 62756-452_ee3c8bae-88f0-4b76-80af-98a3e3312585
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: octreotide acetate
Dosage form: INJECTION
Route: SUBCUTANEOUS
Labeler: Sun Pharmaceutical Industries, Inc.
Application: NDA213224
Marketing category: NDA
Marketing start: 2025-02-24
Substance: OCTREOTIDE ACETATE
Active strength: 2.5 mg/mL
Pharmacologic classes: Somatostatin Analog [EPC], Somatostatin Receptor Agonists [MoA]
NDC exclude flag: No
Listing certified through: 2026-12-31
Current FDA listing: Yes

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 15 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Snapshot	Source SHA-256
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	62756-452-37	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	62756-452-36	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	62756-452-37	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	62756-452-36	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	62756-452-37	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	62756-452-36	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	62756-452-37	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	62756-452-36	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	62756-452-37	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	62756-452-36	`367a005e9d99…`	`383a685ebd0f…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	RLD / RS	Approval date
N213224-001	BYNFEZIA PEN	OCTREOTIDE ACETATE	EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)	SOLUTION / SUBCUTANEOUS		RLD, RS	2024-09-27

Orange Book patents#

Current patent rows page 1 of 1 · 13 matching rows.

Application-product, Patent, Expiration table
Application-product	Patent	Expiration	Use code	Coverage / status	Submission date
N213224-001	10342850	2038-05-15		Drug product	2024-10-18
N213224-001	11052196	2040-11-03	U-4007		2024-10-18
N213224-001	11052196	2040-11-03	U-4008		2024-10-18
N213224-001	11052196	2040-11-03	U-4009		2024-10-18
N213224-001	11246991	2040-11-03	U-4007		2024-10-18
N213224-001	11246991	2040-11-03	U-4008		2024-10-18
N213224-001	11246991	2040-11-03	U-4009		2024-10-18
N213224-001	11534553	2040-11-03	U-4007		2024-10-18
N213224-001	11534553	2040-11-03	U-4008		2024-10-18
N213224-001	11534553	2040-11-03	U-4009		2024-10-18
N213224-001	12350475	2041-12-29	U-4007		2025-07-23
N213224-001	12350475	2041-12-29	U-4008		2025-07-23
N213224-001	12350475	2041-12-29	U-4009		2025-07-23

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-09-14 22:38:34	2026-08	N213224-001	BYNFEZIA PEN	EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2024-09-27	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N213224-001	BYNFEZIA PEN	EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2024-09-27	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N213224-001	BYNFEZIA PEN	EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2024-09-27	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N213224-001	BYNFEZIA PEN	EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2024-09-27	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N213224-001	BYNFEZIA PEN	EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2024-09-27	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N213224-001	BYNFEZIA PEN	EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2024-09-27	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N213224-001	BYNFEZIA PEN	EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2024-09-27	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N213224-001	BYNFEZIA PEN	EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2024-09-27	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N213224-001	BYNFEZIA PEN	EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2024-09-27	`2680178bc6a6…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N213224-001	BYNFEZIA PEN	7MG/2.8ML (2.5MG/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2024-09-27	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N213224-001	BYNFEZIA PEN	7MG/2.8ML (2.5MG/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2024-09-27	`d06236e962d9…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N213224-001	BYNFEZIA PEN	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2020-01-28	`87673890dc5c…`
2021-03-12 10:30 UTC	2021-03	N213224-001	BYNFEZIA PEN	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2020-01-28	`5aa47cf7b7d7…`
2020-12-22 03:56 UTC	2020-12	N213224-001	BYNFEZIA PEN	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2020-01-28	`8869cabd3fbd…`
2020-11-12 02:37 UTC	2020-11	N213224-001	BYNFEZIA PEN	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2020-01-28	`c0c555d07b60…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	N213224-001	BYNFEZIA PEN	EQ 7MG BASE/2.8ML (EQ 2.5MG BASE/ML)	SOLUTION / SUBCUTANEOUS	RLD, RS	2024-09-27	`a50c72e98297…`

Observed Orange Book patent history#

Patent history page 1 of 4 · 133 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Patent	Expiration	Use code	Coverage / status	Submission date	Source SHA-256
2026-09-14 22:38:34	2026-08	N213224-001	10342850	2038-05-15		Drug product	2024-10-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N213224-001	11052196	2040-11-03	U-4007		2024-10-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N213224-001	11052196	2040-11-03	U-4008		2024-10-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N213224-001	11052196	2040-11-03	U-4009		2024-10-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N213224-001	11246991	2040-11-03	U-4007		2024-10-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N213224-001	11246991	2040-11-03	U-4008		2024-10-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N213224-001	11246991	2040-11-03	U-4009		2024-10-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N213224-001	11534553	2040-11-03	U-4007		2024-10-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N213224-001	11534553	2040-11-03	U-4008		2024-10-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N213224-001	11534553	2040-11-03	U-4009		2024-10-18	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N213224-001	12350475	2041-12-29	U-4007		2025-07-23	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N213224-001	12350475	2041-12-29	U-4008		2025-07-23	`84e616aacf4f…`
2026-09-14 22:38:34	2026-08	N213224-001	12350475	2041-12-29	U-4009		2025-07-23	`84e616aacf4f…`
2026-08-18 06:07:40	2026-07	N213224-001	10342850	2038-05-15		Drug product	2024-10-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213224-001	11052196	2040-11-03	U-4007		2024-10-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213224-001	11052196	2040-11-03	U-4008		2024-10-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213224-001	11052196	2040-11-03	U-4009		2024-10-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213224-001	11246991	2040-11-03	U-4007		2024-10-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213224-001	11246991	2040-11-03	U-4008		2024-10-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213224-001	11246991	2040-11-03	U-4009		2024-10-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213224-001	11534553	2040-11-03	U-4007		2024-10-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213224-001	11534553	2040-11-03	U-4008		2024-10-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213224-001	11534553	2040-11-03	U-4009		2024-10-18	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213224-001	12350475	2041-12-29	U-4007		2025-07-23	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213224-001	12350475	2041-12-29	U-4008		2025-07-23	`caaa826d4ba7…`
2026-08-18 06:07:40	2026-07	N213224-001	12350475	2041-12-29	U-4009		2025-07-23	`caaa826d4ba7…`
2026-02-19 14:30 UTC	2026-02	N213224-001	10342850	2038-05-15		Drug product	2024-10-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213224-001	11052196	2040-11-03	U-4007		2024-10-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213224-001	11052196	2040-11-03	U-4008		2024-10-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213224-001	11052196	2040-11-03	U-4009		2024-10-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213224-001	11246991	2040-11-03	U-4007		2024-10-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213224-001	11246991	2040-11-03	U-4008		2024-10-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213224-001	11246991	2040-11-03	U-4009		2024-10-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213224-001	11534553	2040-11-03	U-4007		2024-10-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213224-001	11534553	2040-11-03	U-4008		2024-10-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213224-001	11534553	2040-11-03	U-4009		2024-10-18	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213224-001	12350475	2041-12-29	U-4007		2025-07-23	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213224-001	12350475	2041-12-29	U-4008		2025-07-23	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N213224-001	12350475	2041-12-29	U-4009		2025-07-23	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N213224-001	10342850	2038-05-15		Drug product	2024-10-18	`31067a03dcf5…`

Additional Listing Data#

Finished product: Yes
Brand name base: BYNFEZIA Pen
Listing expiration: 2026-12-31

Active Ingredients#

Ingredient, Strength table
Ingredient	Strength
OCTREOTIDE ACETATE	2.5 mg/mL

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
75R0U2568I	Internal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 2 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
2360543	Internal RxNorm lookup
2360548	Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
20ed4e79-ad4c-426f-859d-83790c00439b	Available on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
813db1d8-6534-4d2d-be9e-8d2c20a55eda	Product name	1	20241217
a6ddfef5-d553-2919-73fa-8aede2a8ab27	Product name	5	20240823
fb7ab793-2c12-4079-b100-a64f73bef25a	Product name	4	20240712
b0cbf770-6cc3-4aa4-9158-755110c2b9f7	Product name	2	20230717
dc7c5daa-021f-40dd-b00d-63982cb2067a	Product name	1	20230426
a62a50ac-1535-4461-9768-8ae703e2e9fb	Product name	1	20210525
8f3fde6c-976e-4e4c-8ed4-542294fcc0ef	Product name	1	20210115
f52be47f-7aa7-46c0-b1fa-50c18dd50206	Product name	1	20201029
08ffbcbf-26df-b99c-1dab-64fc4cfae89f	Product name	5	20200925
467fba3a-c020-419e-8102-aeb9c0ea15ec	Product name	1	20200616
444b3e50-f226-46ef-bfca-2e7035d140cd	Product name	1	20190611
816b97af-edc5-4060-aff1-b814bdbcad50	Product name	1	20190415
7cda52fc-125f-421c-8fea-bc1974370c49	Product name	2	20180703
419aab54-5d5a-4146-9453-026d4a9991be	Product name	2	20170525
08ffbcbf-26df-b99c-1dab-64fc4cfae89f	Product name	2	20160823
89dac932-b90a-4410-9ab1-84c53e57de25	Product name	1	20150316
597b1cfd-7b31-5048-62be-ca5cd740da2f	Product name	1	20140508
9514609b-a2a9-f8ec-6ba6-3f8e5ee89877	Product name	1	20140508
bc07ef78-e82d-0c19-31f4-31f263780582	Product name	1	20140508
ec2149b3-5c6d-5344-f757-c86411073075	Product name	1	20140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Related label table
NDC	Effective	Related label
62756-452-36	2025-02-07	These highlights do not include all the information needed to use BYNFEZIA PEN safely and effectively. See full prescribing information for BYNFEZIA PEN. BYNFEZIA PEN ® (octreotide acetate) injection, for subcutaneous use Initial U.S. Approval: 1988
62756-452-37	2025-02-07	These highlights do not include all the information needed to use BYNFEZIA PEN safely and effectively. See full prescribing information for BYNFEZIA PEN. BYNFEZIA PEN ® (octreotide acetate) injection, for subcutaneous use Initial U.S. Approval: 1988
62756-452-36	2023-01-30	These highlights do not include all the information needed to use BYNFEZIA PEN safely and effectively. See full prescribing information for BYNFEZIA PEN. BYNFEZIA PEN ® (octreotide acetate) injection, for subcutaneous use Initial U.S. Approval: 1988
62756-452-37	2023-01-30	These highlights do not include all the information needed to use BYNFEZIA PEN safely and effectively. See full prescribing information for BYNFEZIA PEN. BYNFEZIA PEN ® (octreotide acetate) injection, for subcutaneous use Initial U.S. Approval: 1988

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	SPL version
62756-452-36	BYNFEZIA Pen	2.8 mL in 1 CARTRIDGE	INJECTION	2.8	5
62756-452-36	BYNFEZIA Pen	1 in 1 CARTON	INJECTION	1	5
62756-452-37	BYNFEZIA Pen	2 in 1 CARTON	INJECTION	2	5
62756-452-37	BYNFEZIA Pen	2.8 mL in 1 CARTRIDGE	INJECTION	2.8	5

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
62756-452-36	ML - Milliliter	62756-452	e8172a04-8a00-4086-a324-c9feed1765df	1	2020-06-05
62756-452-37	ML - Milliliter	62756-452	481af9c4-1d97-4e50-a0cf-1c03a3605fb8	1	2024-12-10

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDC	Dashboard title	SPL version	Validation	Dashboard ZIP
62756-452	BYNFEZIA PEN (OCTREOTIDE ACETATE) INJECTION [SUN PHARMACEUTICAL INDUSTRIES, INC.]	5	Current NDC, Legacy NDC, 4 package rows	20250225_20ed4e79-ad4c-426f-859d-83790c00439b.zip

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
BYNFEZIA Pen	OCTREOTIDE ACETATE	Sun Pharmaceutical Industries, Inc.	20ed4e79-ad4c-426f-859d-83790c00439b	2025-02-21	Warnings, Adverse reactions	Exact identifier application applno (NDA): 213224 application number: NDA213224 ndc (product): 62756-452

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
75R0U2568I	OCTREOTIDE ACETATE	79517-01-4	OCTREOTIDE ACETATE

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
2360548	Bynfezia 2500 MCG/ML in 2.8 ML Pen Injector	PSN	20ed4e79-ad4c-426f-859d-83790c00439b	5
2360543	octreotide 2500 MCG/ML in 2.8 ML Pen Injector	PSN	20ed4e79-ad4c-426f-859d-83790c00439b	5
2360548	2.8 ML octreotide 2.5 MG/ML Pen Injector [Bynfezia]	SBD	20ed4e79-ad4c-426f-859d-83790c00439b	5
2360543	2.8 ML octreotide 2.5 MG/ML Pen Injector	SCD	20ed4e79-ad4c-426f-859d-83790c00439b	5
2360548	Bynfezia 2.5 MG/ML per 2.8 ML Pen Injector	SY	20ed4e79-ad4c-426f-859d-83790c00439b	5
2360548	Bynfezia 2500 MCG/ML per 2.8 ML Pen Injector	SY	20ed4e79-ad4c-426f-859d-83790c00439b	5
2360543	octreotide (as octreotide acetate) 2.5 MG/ML per 2.8 ML Pen Injector	SY	20ed4e79-ad4c-426f-859d-83790c00439b	5
2360543	octreotide (as octreotide acetate) 2500 MCG/ML per 2.8 ML Pen Injector	SY	20ed4e79-ad4c-426f-859d-83790c00439b	5
2360543	octreotide (as octreotide acetate) 7000 MCG per 2.8 ML Pen Injector	SY	20ed4e79-ad4c-426f-859d-83790c00439b	5

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Marketing start	Marketing end	Sample	Exclude flag	Status
62756-452-36	62756045236	1 CARTRIDGE in 1 CARTON (62756-452-36) / 2.8 mL in 1 CARTRIDGE	1 cartridge	2025-02-24	0000-00-00	No	No	Current
62756-452-37	62756045237	2 CARTRIDGE in 1 CARTON (62756-452-37) / 2.8 mL in 1 CARTRIDGE	2 cartridge	2025-02-24	0000-00-00	No	No	Current

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
BYNFEZIA Pen	Sun Pharmaceutical Industries, Inc. \| OneSource Specialty Pharma Limited	2025-02-21	Human Prescription Drug Label	5